Iron Metabolism Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

IRON MCID: IRN002 MIFTS: 58	Iron Metabolism Disease (IRON) Categories: Blood diseases, Endocrine diseases, Metabolic diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Iron Metabolism Disease

MalaCards integrated aliases for Iron Metabolism Disease:

Name: Iron Metabolism Disease ¹¹ ¹⁴

Iron Deficiency ⁷⁵ ⁵³ ⁷¹ ³¹ ³³

Iron Metabolism Disorders ⁴³ ⁷¹

Iron Disorder ¹¹ ⁵³

Disorder of Iron Metabolism ¹¹

Iron Storage Disorder ³³

Iron Storage Disease ³³

Fe Deficiency ³³

Iron ⁴¹

Classifications:

MalaCards categories:
Global: Metabolic diseases
Anatomical: Endocrine diseases Respiratory diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Endocrine, nutritional and metabolic diseases

Metabolic disorders

Disorders of mineral metabolism

Disorders of iron metabolism

Other nutritional deficiencies

Deficiency of other nutrient elements

Iron deficiency

ICD11: ³³

Endocrine, nutritional or metabolic diseases

Metabolic disorders

Disorders of metabolite absorption or transport

Disorders of mineral absorption or transport

Disorders of iron metabolism

Disorders of iron metabolism, unspecified

Other specified disorders of iron metabolism

Nutritional disorders

Undernutrition

Mineral deficiencies

Iron deficiency

External Ids:

Disease Ontology ¹¹ DOID:2351

ICD9CM ³⁴ 275.0

MeSH ⁴³ D019189

SNOMED-CT ⁶⁸ 30913008

ICD10 ³¹ E61.1 E83.1

ICD11 ³³ 362161517 396058882 396058882/other more

UMLS ⁷¹ C0012715 C0240066

Sources

Summaries for Iron Metabolism Disease

MedlinePlus: ⁴¹ Iron is a mineral that our bodies need for many functions. For example, iron is part of hemoglobin, a protein which carries oxygen from our lungs throughout our bodies. It helps our muscles store and use oxygen. Iron is also part of many other proteins and enzymes. Your body needs the right amount of iron. If you have too little iron, you may develop iron deficiency anemia. Causes of low iron levels include blood loss, poor diet, or an inability to absorb enough iron from foods. People at higher risk of having too little iron are young children and women who are pregnant or have periods. Too much iron can damage your body. Taking too many iron supplements can cause iron poisoning. Some people have an inherited disease called hemochromatosis. It causes too much iron to build up in the body. Centers for Disease Control and Prevention

MalaCards based summary: Iron Metabolism Disease, also known as iron deficiency, is related to neurodegeneration with brain iron accumulation 1 and neurodegeneration with brain iron accumulation 3. An important gene associated with Iron Metabolism Disease is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Transport of inorganic cations/anions and amino acids/oligopeptides and Glucose / Energy Metabolism. The drugs Dopamine and Orange have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and lymph node, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia: ⁷⁵ Iron deficiency, or sideropenia, is the state in which a body lacks enough iron to supply its needs.... more...

Sources

Related Diseases for Iron Metabolism Disease

Diseases related to Iron Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2570)

#	Related Disease	Score	Top Affiliating Genes
1	neurodegeneration with brain iron accumulation 1	32.8	SLC11A2 FTL CP
2	neurodegeneration with brain iron accumulation 3	32.3	SLC11A2 IREB2 FTL CP ACO1
3	hemochromatosis, type 5	32.1	TFR2 HJV HFE FTL
4	friedreich ataxia	31.7	TFRC IREB2 HFE FTL ACO1
5	hemochromatosis, type 2b	31.6	TFR2 HJV HFE HAMP FTL
6	neurodegeneration with brain iron accumulation	31.6	TFRC TFR2 SLC40A1 SLC11A2 IREB2 HFE
7	anemia, congenital dyserythropoietic, type ia	31.6	TFRC HJV HAMP EPO
8	hemochromatosis, type 3	31.4	TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
9	hemochromatosis, type 4	31.1	TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
10	vitamin b12 deficiency	30.9	HAMP EPO CRP
11	hemosiderosis	30.9	TFRC TFR2 TF SLC40A1 SLC11A2 HJV
12	thalassemia minor	30.8	HBB HAMP EPO
13	nutritional deficiency disease	30.8	TFRC TF SLC11A2 HJV HAMP EPO
14	porphyria cutanea tarda	30.6	TFRC TFR2 TF SLC40A1 HJV HFE
15	sickle cell disease	30.6	HBB G6PD EPO
16	hfe hemochromatosis	30.6	TF HFE
17	restless legs syndrome	30.5	TFRC SLC11A2 IREB2 HAMP FTL EPO
18	arthropathy	30.5	HJV HFE HAMP FTL CRP
19	polycythemia vera	30.4	TFRC HAMP EPO CRP
20	iron overload	30.3	TFR2 TF SLC40A1 SLC11A2 HJV HFE
21	polycythemia	30.3	TFRC HBB HAMP EPO CRP
22	alpha-thalassemia	30.3	TFRC HFE HBB HAMP G6PD EPO
23	alcohol use disorder	30.3	TF HFE CRP
24	thalassemia	30.3	TFRC TFR2 TF SLC40A1 HJV HFE
25	aceruloplasminemia	30.2	TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
26	sickle cell anemia	30.2	TFRC HBB HAMP G6PD EPO CRP
27	neutropenia	30.2	TFRC EPO CRP CP
28	marasmus	30.2	TF CRP
29	asphyxia neonatorum	30.2	EPO CRP
30	hypogonadotropic hypogonadism	30.2	TFR2 SLC40A1 HFE HBB
31	pancytopenia	30.2	FTL EPO CRP CP
32	alpha-1-antitrypsin deficiency	30.2	IREB2 HFE HAMP
33	hemoglobin e disease	30.1	TFRC HBB
34	acute porphyria	30.0	IREB2 HFE HAMP ACO1
35	glucosephosphate dehydrogenase deficiency	30.0	HBB G6PD CRP
36	folic acid deficiency anemia	30.0	HAMP EPO CRP
37	pulmonary tuberculosis	30.0	SLC11A1 CRP CP
38	chronic pyelonephritis	29.9	EPO CRP
39	macrophage activation syndrome	29.9	FTL CRP
40	plasmodium vivax malaria	29.9	TFRC MT-CYB G6PD
41	anemia, autoimmune hemolytic	29.9	G6PD EPO CRP
42	retinal degeneration	29.9	TFRC SLC11A2 HEPH EPO CP
43	cutaneous porphyria	29.9	HFE HAMP
44	hemoglobin h disease	29.9	TFRC HBB HAMP
45	anemia of prematurity	29.8	TFRC HAMP EPO
46	hemoglobinopathy	29.8	TFRC TFR2 TF HFE HBB HAMP
47	gilbert syndrome	29.8	HFE G6PD CRP
48	splenic sequestration	29.8	HBB EPO
49	analbuminemia	29.8	TF EPO CRP
50	sideroblastic anemia	29.7	TFRC TFR2 SLC40A1 HJV HFE HAMP

Comorbidity relations with Iron Metabolism Disease via Phenotypic Disease Network (PDN):

Deficiency Anemia

Pulmonary Hemosiderosis

Graphical network of the top 20 diseases related to Iron Metabolism Disease:

Sources

Symptoms & Phenotypes for Iron Metabolism Disease

MGI Mouse Phenotypes related to Iron Metabolism Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.32	ACO1 CP CRP CYBRD1 EPO FTL
2	liver/biliary system	MP:0005370	10.25	CP CYBRD1 EPO FTL HAMP HBB
3	nervous system	MP:0003631	10.17	CP FTL G6PD HEPH HFE HJV
4	immune system	MP:0005387	10.16	CP CRP EPO FTL G6PD HAMP
5	cardiovascular system	MP:0005385	10.13	CP CRP EPO FTL G6PD HEPH
6	hematopoietic system	MP:0005397	10.09	ACO1 CP EPO FTL G6PD HAMP
7	mortality/aging	MP:0010768	9.8	ACO1 EPO FTL G6PD HAMP HBB
8	integument	MP:0010771	9.28	HBB HEPH HJV IREB2 SLC11A1 SLC11A2

Sources

Drugs & Therapeutics for Iron Metabolism Disease

Drugs for Iron Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Orange

Approved

Phase 4

Darbepoetin alfa

Approved, Investigational

Phase 4

209810-58-2

Ferrous gluconate

Approved

Phase 4

299-29-6

Halofantrine

Approved

Phase 4

69756-53-2

37393

Nicotinamide

Approved, Investigational

Phase 4

98-92-0

936

Interferon beta-1a

Approved, Investigational

Phase 4

145258-61-3

Mecobalamin

Approved, Investigational

Phase 4

13422-55-4

Hydroxocobalamin

Approved

Phase 4

13422-51-0

15589840 44475014

Ferrous succinate

Approved

Phase 4

10030-90-7

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Ferric maltol

Approved

Phase 4

33725-54-1

Ferrous fumarate

Approved

Phase 4

141-01-5

Deferasirox

Approved, Investigational

Phase 4

201530-41-8

214348 5493381

Deferoxamine

Approved, Investigational

Phase 4

70-51-9

2973

Pyridoxine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

65-23-6

1054

Glycine

Approved, Nutraceutical, Vet_approved

Phase 4

56-40-6

750

Aspartic acid

Approved, Nutraceutical

Phase 4

56-84-8

5960

Niacin

Approved, Investigational, Nutraceutical

Phase 4

59-67-6

938

Riboflavin

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

83-88-5

493570

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Ascorbic acid

Approved, Nutraceutical

Phase 4

50-81-7

54676860 54670067 5785

Cyanocobalamin

Approved, Nutraceutical

Phase 4

68-19-9

24892734 16212801 44176380

Thiamine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

70-16-6

1130

Cobalamin

Experimental

Phase 4

13408-78-1

6857388

Trichostatin A

Experimental

Phase 4

58880-19-6

5562 444732

Anesthetics

Phase 4

Vitamin B6

Phase 4

Vitamin B 6

Phase 4

Teferrol

Phase 4

Neurotransmitter Agents

Phase 4

Caseins

Phase 4

N-Methylaspartate

Phase 4

Vitamin B3

Phase 4

Nicotinic Acids

Phase 4

Vitamin B2

Phase 4

Chondroitin

Phase 4

9007-27-6

14389182

Zinc Supplement

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Vaccines

Phase 4

Vitamin B12

Phase 4

Vitamin B 12

Phase 4

Vitamin B1

Phase 4

Thiamin

Phase 4

Blood Substitutes

Phase 4

Anticoagulants

Phase 4

Plasma Substitutes

Phase 4

Interventional clinical trials:

(show top 50) (show all 1312)

#	Name	Status	NCT ID	Phase	Drugs
1	Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia.	Unknown status	NCT00199277	Phase 4	i.v. iron sucrose;Oral iron
2	A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency	Unknown status	NCT03344523	Phase 4	Iron protein succinylate oral solution
3	A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting	Unknown status	NCT01950247	Phase 4	Injectafer;SOC
4	the Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis	Unknown status	NCT03748043	Phase 4	Lactoferrin;Ferric Hydroxide Polymaltose
5	Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability	Unknown status	NCT03359447	Phase 4	Weekly Ferrous Sulfate;Daily Ferrous Sulfate
6	Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency	Unknown status	NCT00479102	Phase 4	Ferripel-3 - iron polysaccharide complex for prevention
7	Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy?	Unknown status	NCT03347513	Phase 4	triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
8	Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease	Unknown status	NCT02774057	Phase 4	Captafer®;Iron Sulfate
9	Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial	Unknown status	NCT03830034	Phase 4	Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
10	Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial	Unknown status	NCT03202615	Phase 4	F (ferrous sulphate)
11	Iron Deficiency as an Ignored Cause of Infertility	Unknown status	NCT04510870	Phase 4	Ferric Carboxymaltose Injection;NaCl infusion
12	Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial.	Unknown status	NCT02242188	Phase 4	Iron
13	The Role Of IV Iron (Ferric Carboxymaltose) And IM Vitamin B12 (Hydroxycobalamin) Supplementation In The Management Of Anaemic Prevalent Indian Hemodialysis Patients: A Parallel Group, Quadruple Blind, Placebo-Controlled, Pragmatic Randomized Control Trial With 2x2 Factorial Design	Unknown status	NCT04627181	Phase 4	Ferric carboxymaltose;Hydroxycobalamin;Placebo
14	Ferritin Screening And IRon Treatment for Maternal Anemia and Fetal Growth Restriction (FGR) Prevention - a Multi Centre Randomised Controlled Trial (RCT)	Unknown status	NCT04228627	Phase 4	Parentral Iron
15	The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery	Unknown status	NCT02999217	Phase 4	Iron isomaltoside;Saline
16	Double-Blind, Single-Center Interventional Trial To Evaluate The Effect Of Intravenous Iron Versus Placebo On Cerebral Dopamine Receptor Density In Non Anaemic Premenopausal Women With Low Ferritin Levels And Fatigue	Unknown status	NCT03305705	Phase 4	Iron Carboxymaltose;Sodium chloride 0.9%
17	Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe	Unknown status	NCT02487719	Phase 4	Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
18	a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year	Unknown status	NCT03171324	Phase 4	Iron Supplement
19	Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations.	Unknown status	NCT00248716	Phase 4	Ferrous gluconate and iron polysaccharide complex
20	The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children	Unknown status	NCT01418898	Phase 4
21	Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial	Unknown status	NCT03229954	Phase 4	iron isomaltoside (Monofer) intravenous infusion;Ferrous sulfate(Feroba-YOU) per oral
22	Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension	Unknown status	NCT01288651	Phase 4	Ferricarboxymaltose
23	Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias	Unknown status	NCT02443545	Phase 4	Deferiprone
24	The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF).	Unknown status	NCT03871699	Phase 4	Ferric carboxymaltose
25	Preoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot)	Unknown status	NCT03295851	Phase 4	Ferric carboxymaltose;Ferrous Fumarate
26	An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma	Unknown status	NCT01927328	Phase 4	Iron isomaltoside 1000
27	Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone	Unknown status	NCT02731378	Phase 4	Erythropoietins (EPO);Aggressive iron dextran supplementation;Sustained iron dextran supplementation
28	Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy	Unknown status	NCT02612870	Phase 4
29	Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment	Unknown status	NCT02760940	Phase 4	oral liposomal iron
30	Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients	Unknown status	NCT02243735	Phase 4	Ferrous fumarate;ferric(III)carboxymaltose
31	Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery?	Unknown status	NCT02544828	Phase 4	Iron Sucrose 200mg;placebo
32	Intraoperative IV Iron on the Postoperative Recovery of Red Blood Cell in Hip Arthroplasty Surgery	Unknown status	NCT04035902	Phase 4	Ferric carboxymaltose;control
33	Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia	Unknown status	NCT01084122	Phase 4	Iron sucrose
34	Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients	Unknown status	NCT02416778	Phase 4	Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
35	Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease	Unknown status	NCT00204256	Phase 4	Iron sucrose
36	A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance	Unknown status	NCT00103753	Phase 4	deferiprone
37	Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC	Unknown status	NCT01795794	Phase 4	omeprazole
38	Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women	Completed	NCT01221844	Phase 4	FerroGrad by Abbott
39	The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA)	Completed	NCT02631668	Phase 4	ferrous succinate and vitamin C;ferrous succinate
40	Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.	Completed	NCT02031289	Phase 4	Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
41	Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass	Completed	NCT02086968	Phase 4	Injectafer;Ferrous Sulfate tablets
42	A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia.	Completed	NCT01904864	Phase 4	elemental iron (NovaFerrum®);elemental iron (Ferrous Sulfate)
43	Lactoferrin Efficacy Versus Ferrous Sulfate in Treatment of Patients With Iron Deficiency Anemia	Completed	NCT04267653	Phase 4	Lactoferrin Bovine;Ferrous Sulfate
44	Rationale and Design of Ferric Polymaltose Hydroxide and Iron Sucrose Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study	Completed	NCT04225728	Phase 4	Iron Sucrose IV;Ferric polymaltose hydroxide complex IM
45	Ferrous Bis-glycinate Versus Ferrous Glycine Sulfate for the Treatment of Iron Deficiency Anemia During Pregnancy	Completed	NCT02590224	Phase 4	Ferrous bis-glycinate;Ferrous glycine sulphate
46	A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia	Completed	NCT00802139	Phase 4	venoferrum(iron sucrose);Bolgre (Iron acetyl-transferase)
47	Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial	Completed	NCT00746551	Phase 4	Ferli-6® (Continental Pharm co., ltd.);Venofer® (Vifor AG, St. Gallen, Switzerland)
48	Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue	Completed	NCT01991314	Phase 4	Ferrous sulphate
49	Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial	Completed	NCT03836703	Phase 4	Feroglobin single daily use;Feroglobin twice daily dose
50	Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)	Completed	NCT02642562	Phase 4	Ferric Derisomaltose

Search NIH Clinical Center for Iron Metabolism Disease

Cochrane evidence based reviews: iron metabolism disorders

Sources

Genetic Tests for Iron Metabolism Disease

Sources

Anatomical Context for Iron Metabolism Disease

Organs/tissues related to Iron Metabolism Disease:

MalaCards : Kidney, Heart, Lymph Node, Liver, Brain, Skeletal Muscle, Breast

Sources

Publications for Iron Metabolism Disease

Articles related to Iron Metabolism Disease:

(show top 50) (show all 47246)

#	Title	Authors	PMID	Year
1	New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. ⁴¹	Kontoghiorghes GJ	36430469	2022
2	The Association between Iron and Folic Acid Supplementation and Malaria Prophylaxis and Linear Growth among Children and Neonatal Mortality in Sub-Saharan Africa-A Pooled Analysis. ⁴¹	Godha D...Cisse AS	36364759	2022
3	Probability of non-compliance to the consumption of Iron Tablets in pregnant women in Indonesia. ⁴¹	Noptriani S...Simbolon D	36415291	2022
4	Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. ⁵³ ⁶²	Lulla RR...Liem RI	20486179	2010
5	Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. ⁵³ ⁶²	Ayoya MA...Garza C	20410090	2010
6	Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. ⁵³ ⁶²	Miwa N...Tsuchiya K	19624802	2010
7	Posttransplant anemia in solid organ recipients. ⁵³ ⁶²	Blosser CD...Bloom RD	20303457	2010
8	Ceramide in suicidal death of erythrocytes. ⁵³ ⁶²	Lang F...Foller M	20502001	2010
9	Iron stores, periodic leg movements, and sleepiness in obstructive sleep apnea. ⁵³ ⁶²	O'Brien LM...Chervin RD	20465018	2009
10	[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. ⁵³ ⁶²	Zorgati MM...Ben Ammar S	20209848	2009
11	The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. ⁵³ ⁶²	Herbison CE...Trinder D	19828835	2009
12	Ferric carboxymaltose in patients with heart failure and iron deficiency. ⁵³ ⁶²	Anker SD...FAIR-HF Trial Investigators	19920054	2009
13	Impact of socioeconomic and health related factors on the iron status of adolescent girls from two boarding schools in Southern Benin. ⁵³ ⁶²	Alaofe H...O'Brien HT	20306766	2009
14	[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)]. ⁵³ ⁶²	Lovcic V...Dzapo M	20232547	2009
15	Transferrin and ferritin response to bacterial infection: the role of the liver and brain in fish. ⁵³ ⁶²	Neves JV...Rodrigues PN	19428486	2009
16	Differential ferritin expression is associated with iron deficiency in coeliac disease. ⁵³ ⁶²	Sharma N...Iqbal TH	19404207	2009
17	Influence of inflammation as measured by alpha-1-acid glycoprotein on iron status indicators among HIV-positive postpartum Zimbabwean women. ⁵³ ⁶²	Rawat R...Humphrey JH	18506200	2009
18	Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index. ⁵³ ⁶²	Ooi CL...Filler G	19718534	2009
19	Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. ⁵³ ⁶²	Wander K...McDade TW	18949769	2009
20	Abnormal brain iron homeostasis in human and animal prion disorders. ⁵³ ⁶²	Singh A...Singh N	19283067	2009
21	Early effects on T lymphocyte response to iron deficiency in mice. Short communication. ⁵³ ⁶²	Saldanha-Araujo F...Souza AM	18825318	2009
22	Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. ⁵³ ⁶²	Shah YM...Gonzalez FJ	19147412	2009
23	Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. ⁵³ ⁶²	Jiao Y...Torti SV	18815282	2009
24	Differing expression of genes involved in non-transferrin iron transport across plasma membrane in various cell types under iron deficiency and excess. ⁵³ ⁶²	Balusikova K...Kovar J	18830567	2009
25	The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. ⁵³ ⁶²	Metzgeroth G...Hastka J	19743956	2009
26	Suicide for survival--death of infected erythrocytes as a host mechanism to survive malaria. ⁵³ ⁶²	Foller M...Lang F	19710527	2009
27	[Immune, inflammatory, and nutritional protein profile in children with iron deficiency in Côte d'Ivoire]. ⁵³ ⁶²	Yapi HF...Monnet D	19801348	2009
28	Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. ⁵³ ⁶²	Fishbane S...Joffe MM	18987297	2009
29	Parenteral ascorbic acid in haemodialysis patients. ⁵³ ⁶²	Biesalski HK	18827578	2008
30	Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. ⁵³ ⁶²	Shahrbanoo K...Taziki O	18974579	2008
31	Erythrocyte programmed cell death. ⁵³ ⁶²	Foller M...Lang F	18720418	2008
32	[Old and new iron parameters in iron metabolism and diagnostics]. ⁵³ ⁶²	Graf L...Korte W	18791966	2008
33	Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. ⁵³ ⁶²	Chan KE...Moran J	18469314	2008
34	Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. ⁵³ ⁶²	Hedenus M...Liwing J	18613854	2008
35	Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. ⁵³ ⁶²	Wallander ML...Leibold EA	18574241	2008
36	Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure. ⁵³ ⁶²	Choi JW	18317758	2008
37	[Expression of iron regulatory protein-2 and ferritins in intestinal mucosa of rats with iron deficiency]. ⁵³ ⁶²	Zuo WL...Liu YF	18549630	2008
38	Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. ⁵³ ⁶²	Hamada Y...Fukagawa M	18174266	2008
39	Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. ⁵³ ⁶²	Jolobe O	18279424	2008
40	Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. ⁵³ ⁶²	Xu X...Richardson DR	18029550	2008
41	Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. ⁵³ ⁶²	McLaren CE...Hemochromatosis and Iron Overload Screening Study Research Investigators	18201677	2008
42	Potential roles of erythropoietin in the management of anaemia and other complications diabetes. ⁵³ ⁶²	Khoshdel A...Trevillian P	17645562	2008
43	Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. ⁵³ ⁶²	Li H...Wang SX	18212498	2008
44	Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. ⁵³ ⁶²	Kong WN...Duan XL	18306987	2008
45	Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. ⁵³ ⁶²	van der Putten K...Gaillard CA	18094727	2008
46	Prognostic value of reticulocyte hemoglobin content to diagnose iron deficiency in 6-24-month-old children. ⁵³ ⁶²	Kiudeliene R...Labanauskas L	18971604	2008
47	The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. ⁵³ ⁶²	Ozdemir A...Turkmen F	18004086	2007
48	Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. ⁵³ ⁶²	Sahiratmadja E...Marx JJ	17466092	2007
49	Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. ⁵³ ⁶²	Xiong L...Rouleau GA	17510944	2007
50	Inflammation and iron deficiency in the hypoferremia of obesity. ⁵³ ⁶²	Yanoff LB...Yanovski JA	17438557	2007

Sources

Genes for Iron Metabolism Disease

Genes related to Iron Metabolism Disease (0 elite genes):

(show all 24)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HFE	Homeostatic Iron Regulator	Protein Coding	27.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12949720 10772870 10349514 (more) 12145797 12614226 15531451 12547214 18201677 10657371 12401305 11529872 11960574 11358390
2	TF	Transferrin	Protein Coding	23.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12737937 18023212 17376421 (more) 19283067 18971604 8167189 9398141 1524142 17699374 12631092 19428486 17477085 1940402 18815282 2008756 11026519 8503735 19624802 15932566 9555668 9633972 1788107 1307433 8750487 9201139 9835878 9922497 10366790 19920054 9086290 9091669 9007493 8202725 8192528 1558097 1775783 2300955 19379425 20306766 17236123 16930377 16522934 16843187 15635879 11446733 11316861 11042033 1506923 1802636 17036608 16982459 15280908 11349890 10469862 10414620 10543327 16412965 14633776 12716676 11576884 10624905 9836708 9543601 9481720 7511531 1426914 2242107 7852922 18004086 17038573 8132241 8122498 2128750 2280440 20465018 17106764 17722476 15717636 9211366 15231912 12614226 10222489 10193816 10084287 9686711 8796233 7832579 8652956 7846387 1433941 1519605 1566014 1896380 1856046 2318292 10772870 10460349 10412499 9915269 10770093 10682073
3	HJV	Hemojuvelin BMP Co-Receptor	Protein Coding	18.36	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15138164
4	TFRC	Transferrin Receptor	Protein Coding	18.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11063448 12605386 10968236 (more) 17469727 9066706 15104997 14728613 15772926 11725764 12667008 9624883 9812635 18971604 9328369 9703002 17877204 18949769 11737064 10681454 8877341 17254562 16271988 11045146 15054143 9846592 9250113 18042534 12468620 10086785 20209848 17617082 15163319 15755831 2401848 1537518 8055201 9716612 10975004 15820481 19283067 2229063 9222286 8134170 8427988 19718534 18279424 16454050 15942552 9989689 10536931 15816689 15017332 14998307 14641138 12867292 12455576 11013867 10344669 2070061 11601029 8092098 1957824 20486179 17727315 17532764 19828835 18825318 18791966 17438557 16520941 15810798 15698591 14633776 9490571 8327847 12885710 12589962 12458802 11508389 10865494 10971831 9550557 9543601 19743956 18029550 17105489 12521853 10518614 9299946 9007493 9280000 18506200 18317758 17019689 17013644 16280445 12571434 11313310 10827206
5	SLC11A2	Solute Carrier Family 11 Member 2	Protein Coding	17.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11313311 12547214 15054143 (more) 14618243 11042033 11159549 12572674 12801950 18830567 12209011 12949888 10954338 19147412 10049947 17510944 18174266 19404207 10417735
6	EPO	Erythropoietin	Protein Coding	17.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12647284 15784734 9352960 (more) 8524494 17106764 9561479 11887826 16736414 8448609 10543327 9102827 7872320 16645227 9491286 9267720 10366799 9934812 11126152 10084294 7999415 11422765 16198278 15737895 9804503 9415935 8142226 1552389 8171931 8004833 7999811 7881986 8659499 9159297 12735211 7949539 8227911 1486042 2054965 18974579 18827578 18212498 17373278 16949463 9180431 8989744 1519605 20232547 18987297 18209428 18094727 17118231 16336085 17098634 15114602 11902060 11812914 11209002 11132761 10193816 9829492 7586775 11032356 10624905 9892376 9760808 9623555 9211366 9096447 8697726 7970108 8400253 1288287 1574966 18306987 17645562 18613854 16830701 15754276 15686330 12911189 11863124 11759218 11725764 9328369 9260753 9100046 1486041 1739797 20303457 11590254 11475345 10469862 10207271 10645031 9555669 9543911 9540026 16200900 15495089
7	SLC40A1	Solute Carrier Family 40 Member 1	Protein Coding	16.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14618243 12572674 12801950 (more) 18174266 11313311
8	CYBRD1	Cytochrome B Reductase 1	Protein Coding	15.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17087784 12949720 16137899
9	HEPH	Hephaestin	Protein Coding	15.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12949720 16137899 15054143 (more) 18830567
10	IREB2	Iron Responsive Element Binding Protein 2	Protein Coding	14.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18549630 8668195 18574241 (more) 15684386
11	TFR2	Transferrin Receptor 2	Protein Coding	14.69	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10681454
12	ACO1	Aconitase 1	Protein Coding	14.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8668195 17877204 9950149 (more) 9092514 15136682 16503547 16531245
13	FTL	Ferritin Light Chain	Protein Coding	13.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7647009
14	CP	Ceruloplasmin	Protein Coding	13.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10777486 11042176 18830567
15	CRP	C-Reactive Protein	Protein Coding	12.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12647284 16280445 14728613 (more) 17381972 7586775 18469314 20410090 11026519 19801348 15755831
16	MT-CYB	Mitochondrially Encoded Cytochrome B	Protein Coding	8.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16137899 12949720
17	HAMP	Hepcidin Antimicrobial Peptide	Protein Coding	8.59	DISEASES inferred ¹⁴
18	SLC11A1	Solute Carrier Family 11 Member 1	Protein Coding	8.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10417735 17466092
19	G6PD	Glucose-6-Phosphate Dehydrogenase	Protein Coding	8.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19710527 7834228 2249233 (more) 20502001 7628584 18720418
20	HBB	Hemoglobin Subunit Beta	Protein Coding	7.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8342561
21	PANK2	Pantothenate Kinase 2	Protein Coding	7.12	DISEASES inferred ¹⁴
22	TMPRSS6	Transmembrane Serine Protease 6	Protein Coding	7.01	DISEASES inferred ¹⁴
23	ERFE	Erythroferrone	Protein Coding	6.75	DISEASES inferred ¹⁴
24	TTR	Transthyretin	Protein Coding	6.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19801348 10702174 8599325

Sources

Variations for Iron Metabolism Disease

Sources

Expression for Iron Metabolism Disease

Search GEO for disease gene expression data for Iron Metabolism Disease.

Sources

Pathways for Iron Metabolism Disease

Pathways related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	Transport of inorganic cations/anions and amino acids/oligopeptides ⁶⁶ Show member pathways Amino acid transport across the plasma membrane ⁶⁶ Bicarbonate transporters ⁶⁶ Cation-coupled Chloride cotransporters ⁶⁶ Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN) ⁶⁶ Defective SLC12A1 causes Bartter syndrome 1 (BS1) ⁶⁶ Defective SLC12A3 causes Gitelman syndrome (GS) ⁶⁶ Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) ⁶⁶ Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) ⁶⁶ Defective SLC17A5 causes Salla disease (SD) and ISSD ⁶⁶ Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25) ⁶⁶ Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) ⁶⁶ Defective SLC22A12 causes renal hypouricemia 1 (RHUC1) ⁶⁶ Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1) ⁶⁶ Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP) ⁶⁶ Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI) ⁶⁶ Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6) ⁶⁶ Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1) ⁶⁶ Defective SLC26A4 causes Pendred syndrome (PDS) ⁶⁶ Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1) ⁶⁶ Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) ⁶⁶ Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG) ⁶⁶ Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) ⁶⁶ Defective SLC6A5 causes hyperekplexia 3 (HKPX3) ⁶⁶ Defective SLC9A6 causes X-linked, syndromic mental retardation,, Christianson type (MRXSCH) ⁶⁶ Defective SLC9A9 causes autism 16 (AUTS16) ⁶⁶ Inositol transporters ⁶⁶ Multifunctional anion exchangers ⁶⁶ Na+/Cl- dependent neurotransmitter transporters ⁶⁶ Organic anion transport ⁶⁶ Organic anion transporters ⁶⁶ Organic cation transport ⁶⁶ Organic cation/anion/zwitterion transport ⁶⁶ Proton/oligopeptide cotransporters ⁶⁶ Proton-coupled monocarboxylate transport ⁶⁶ Proton-coupled neutral amino acid transporters ⁶⁶ Rhesus glycoproteins mediate ammonium transport. ⁶⁶ SLC-mediated transmembrane transport ⁶⁶ Sodium/Calcium exchangers ⁶⁶ Sodium/Proton exchangers ⁶⁶ Sodium-coupled phosphate cotransporters ⁶⁶ Sodium-coupled sulphate, di- and tri-carboxylate transporters ⁶⁶ Transport of bile salts and organic acids, metal ions and amine compounds ⁶⁶ Transport of small molecules ⁶⁶ Type II Na+/Pi cotransporters ⁶⁶ Variant SLC6A14 may confer susceptibility towards obesity ⁶⁶	12.93	TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
2	Glucose / Energy Metabolism ³	12.4	SLC11A2 IREB2 HBB G6PD CP ACO1
3	Disorders of transmembrane transporters ⁶⁶ Show member pathways SLC transporter disorders ⁶⁶	12.23	SLC40A1 SLC11A2 HEPH CP
4	Metal ion SLC transporters ⁶⁶ Show member pathways Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ) ⁶⁶ Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) ⁶⁶ Metallothioneins bind metals ⁶⁶ MTF1 activates gene expression ⁶⁶ Response to metal ions ⁶⁶ Zinc efflux and compartmentalization by the SLC30 family ⁶⁶ Zinc homeostasis ⁷⁴ Zinc influx into cells by the SLC39 gene family ⁶⁶ Zinc transporters ⁶⁶	11.89	SLC40A1 SLC11A2 SLC11A1 HEPH CP
5	Insulin receptor recycling ⁶⁶ Show member pathways ATP biosynthesis ⁶¹ Events associated with phagocytolytic activity of PMN cells ⁶⁶ Iron uptake and transport ⁶⁶ melatonin degradation III ⁶¹ ROS and RNS production in phagocytes ⁶⁶ Transferrin endocytosis and recycling ⁶⁶	11.67	TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
6	HIF-1-alpha transcription factor network ⁶¹	11.57	TFRC TF EPO CP
7	3q29 copy number variation syndrome ⁷⁴	11.51	TFRC TF SLC40A1 HFE HAMP
8	Ferroptosis ⁷⁴	11.51	CP FTL IREB2 SLC11A2 SLC40A1 TF
9	Iron metabolism in placenta ⁷⁴	10.56	TFR2 SLC40A1 SLC11A2 IREB2 ACO1
10	Hfe effect on hepcidin production ⁷⁴	10.39	HJV HFE HAMP
11	Defective CP causes aceruloplasminemia (ACERULOP) ⁶⁶ Show member pathways Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages) ⁶⁶	10.08	SLC40A1 CP

Sources

GO Terms for Iron Metabolism Disease

Cellular components related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	blood microparticle	GO:0072562	9.86	TFRC TF HBB CP
2	recycling endosome	GO:0055037	9.76	TFRC TF SLC11A2 HFE
3	basal part of cell	GO:0045178	9.43	TF SLC11A2 HFE
4	HFE-transferrin receptor complex	GO:1990712	9.32	TFRC TFR2 TF HJV HFE

Biological processes related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	iron ion homeostasis	GO:0055072	10.23	FTL CYBRD1 CP HAMP HEPH HFE
2	cellular iron ion homeostasis	GO:0006879	10.13	TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
3	establishment of localization in cell	GO:0051649	10.11	SLC40A1 SLC11A2 SLC11A1 IREB2 HAMP
4	acute-phase response	GO:0006953	10.1	CRP EPO HAMP TFR2 TFRC
5	osteoclast differentiation	GO:0030316	10.03	TFRC TF IREB2
6	response to iron ion	GO:0010039	10.03	TFRC TFR2 SLC11A2 HFE HAMP CYBRD1
7	monoatomic ion transport	GO:0006811	10.02	CP HEPH HFE SLC11A1 SLC11A2 SLC40A1
8	multicellular organismal iron ion homeostasis	GO:0060586	10.02	HAMP HFE SLC11A1 SLC11A2 SLC40A1
9	copper ion transport	GO:0006825	9.97	SLC11A2 HEPH CP
10	iron ion transmembrane transport	GO:0034755	9.97	SLC40A1 SLC11A2 SLC11A1 HAMP
11	cellular response to iron ion	GO:0071281	9.91	TFR2 TF HFE
12	positive regulation of peptide hormone secretion	GO:0090277	9.89	TFR2 HFE
13	manganese ion transmembrane transport	GO:0071421	9.88	SLC11A2 SLC11A1
14	transferrin transport	GO:0033572	9.88	TFRC TFR2
15	manganese ion transport	GO:0006828	9.87	SLC11A2 SLC11A1
16	citrate metabolic process	GO:0006101	9.85	ACO1 IREB2
17	cadmium ion transmembrane transport	GO:0070574	9.84	SLC11A1 SLC11A2
18	response to iron ion starvation	GO:1990641	9.83	HFE HAMP
19	regulation of iron ion transport	GO:0034756	9.81	TF HFE
20	iron ion transport	GO:0006826	9.6	CP FTL HEPH IREB2 SLC11A1 SLC11A2

Molecular functions related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	copper ion binding	GO:0005507	9.99	HEPH HAMP CP
2	ferric iron binding	GO:0008199	9.83	TF FTL
3	manganese ion transmembrane transporter activity	GO:0005384	9.8	SLC11A2 SLC11A1
4	ferrous iron binding	GO:0008198	9.8	TF HEPH FTL
5	ferrous iron transmembrane transporter activity	GO:0015093	9.78	SLC40A1 SLC11A2
6	ferroxidase activity	GO:0004322	9.76	HEPH CP
7	cadmium ion transmembrane transporter activity	GO:0015086	9.73	SLC11A2 SLC11A1
8	aconitate hydratase activity	GO:0003994	9.71	ACO1 IREB2
9	iron-responsive element binding	GO:0030350	9.67	ACO1 IREB2
10	transition metal ion transmembrane transporter activity	GO:0046915	9.56	SLC11A2 SLC11A1
11	transferrin receptor activity	GO:0004998	9.46	TFRC TFR2
12	transferrin receptor binding	GO:1990459	9.43	TF HJV HFE
13	iron ion transmembrane transporter activity	GO:0005381	9.1	SLC40A1 SLC11A2 SLC11A1